711 related articles for article (PubMed ID: 28677510)
1. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
Chiang CE; Ferrières J; Gotcheva NN; Raal FJ; Shehab A; Sung J; Henriksson KM; Hermans MP
J Atheroscler Thromb; 2016 May; 23(5):567-87. PubMed ID: 26632163
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
4. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
[TBL] [Abstract][Full Text] [Related]
5. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
6. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
7. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
[TBL] [Abstract][Full Text] [Related]
9. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
[TBL] [Abstract][Full Text] [Related]
10. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
[TBL] [Abstract][Full Text] [Related]
13. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.
Park JE; Chiang CE; Munawar M; Pham GK; Sukonthasarn A; Aquino AR; Khoo KL; Chan HW
Eur J Prev Cardiol; 2012 Aug; 19(4):781-94. PubMed ID: 21450606
[TBL] [Abstract][Full Text] [Related]
15. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
16. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
Al-Zakwani I; Al-Mahruqi F; Al-Rasadi K; Shehab A; Al Mahmeed W; Arafah M; Al-Hinai AT; Al Tamimi O; Al Awadhi M; Santos RD
Lipids Health Dis; 2018 Feb; 17(1):25. PubMed ID: 29402296
[TBL] [Abstract][Full Text] [Related]
17. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
[TBL] [Abstract][Full Text] [Related]
18. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
19. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Hanefeld M; Traylor L; Gao L; Landgraf W
Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
[TBL] [Abstract][Full Text] [Related]
20. Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries.
Arafah M; Al-Hinai AT; Al Mahmeed W; Al-Rasadi K; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FO; Alawadhi M; Amin H; Al-Hashmi K; Shehab A
Angiology; 2014 Nov; 65(10):919-26. PubMed ID: 24301426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
